Avadzadeh, S;
Sharma, A;
Parvaresh, MM;
Ghasemi Falavarjani, K;
Lee, CS;
Sagong, M;
Woo, SJ;
... Kuppermann, BD; + view all
(2025)
Aflibercept 2 mg biosimilar (Tyalia)—real-world experience from IRAN (ATRIA study).
Eye
10.1038/s41433-025-03813-2.
(In press).
![[thumbnail of Keane_Aflibercept 2 mg biosimilar Tyalia—real-world experience from IRAN ATRIA study_AAM.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Keane_Aflibercept 2 mg biosimilar Tyalia—real-world experience from IRAN ATRIA study_AAM.pdf Access restricted to UCL open access staff until 4 May 2026. Download (149kB) |
Abstract
Purpose: To evaluate the early real-world clinical outcomes regarding safety and efficacy after administering the aflibercept 2 mg biosimilar (Tyalia, Cinnagen, Tehran, Iran). Methods: A retrospective, uncontrolled observational study was conducted with a total of 499 Tyalia injections given in 189 eyes of 148 patients for variable indications. All patients were treated with at least one intravitreal injection of Tyalia 2 mg; 102 eyes with neovascular age-related macular degeneration (n-AMD), 67 eyes with diabetic macular oedema (DMO), and 20 eyes with retinal vein occlusion (RVO) associated with macular oedema were included in the analysis. Results: The mean central subfield thickness (CST) of the overall group improved from baseline to the last follow-up from 408.8 ± 155.1 µ to 353.4 ± 142.4 µ (p < 0.001). Best corrected visual acuity was found to be stable in the total cohort. The total number of adverse events (AEs) was (0.4%). Conclusions: The preliminary real-world data from this limited early series suggest that Tyalia appears to have similar clinical efficacy and safety as aflibercept 2 mg innovator across the approved indications. However, long-term data with a larger population are needed to further strengthen the findings of this study.
| Type: | Article |
|---|---|
| Title: | Aflibercept 2 mg biosimilar (Tyalia)—real-world experience from IRAN (ATRIA study) |
| DOI: | 10.1038/s41433-025-03813-2 |
| Publisher version: | https://doi.org/10.1038/s41433-025-03813-2 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10209398 |
Archive Staff Only
 |
View Item |
